NCT06605404ClinicalTrials.gov
Pan-tumor MRD Study
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
In breve
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…
Osservazionale1350 partecipanti ricercati47 centri1 paese
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT06605404Apri questa scheda su ClinicalTrials.govSincronizzato 2 mesi fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
- Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
- The record lists 7 conditions.
- Lead sponsor type recorded as: industry.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation0/20
Allocation not stated in the record
- Blinding0/20
Masking not stated in the record
- Control arm0/15
No comparator arm stated in the record
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre5/8
Multi-centre: 2 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 1,350 participants (target), run at 47 sites.
How this score is built
- Enrolment31/40
1,350 participants (target)
- Site count4/25
2 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 88 months
- Sponsor scale0/10
Paradigm Health has led 1 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.
Patologie
- Muscle Invasive Bladder Urothelial Carcinoma
- Esophageal Cancer
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Melanoma (Skin Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic (Exocrine Only)
- Mix of Solid Tumors (MOST)
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
| Metodo di campionamento | NON_PROBABILITY_SAMPLE |
Popolazione dello studio
Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Osservazionale |
|---|---|
| Fase | Non indicato nella scheda del registro |
| Assegnazione | Non indicato nella scheda del registro |
| Modello di intervento | Non indicato nella scheda del registro |
| Finalità principale | Non indicato nella scheda del registro |
| Mascheramento | Non indicato nella scheda del registro |
| Arruolamento | 1350 partecipanti ricercati |
Sponsor e collaboratori
- Paradigm Health Sponsor
Bracci e interventi
- Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)
- Esophageal
Esophageal cancer
- Gastric and Gastroesophageal Junction (GEJ)
Gastric and Gastroesophageal Junction (GEJ)
- Melanoma
Melanoma
- Non-small cell lung (NSCLC)
Non-small cell lung (NSCLC)
- Pancreatic (exocrine only)
Pancreatic (exocrine only)
- Mix of Solid Tumors (MOST)
Mix of Solid Tumors (MOST)
Interventi
- Test diagnostico blood and tissue samples
routine standard of care
- Altro blood and tissue samples
Routine standard of care
Esiti misurati
Esito primario
Blood and tissue biospecimen registry
To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.
Orizzonte temporale Observation from enrollment to 5.5 years after enrollment
Date
| Data di inizio | 8 gennaio 2025 (effettiva) |
|---|---|
| Conclusione primaria | 1 dicembre 2031 (stimata) |
| Conclusione | 1 aprile 2032 (stimata) |
| Prima pubblicazione | 20 settembre 2024 (effettiva) |
| Ultimo aggiornamento | 24 settembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | settembre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
47 centri stanno reclutando
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Piedmont Cancer Institute | Atlanta | Georgia | In reclutamento |
| Guthrie Lourdes Memorial Hospital (GLMH) | Binghamton | New York | In reclutamento |
| Alabama Oncology | Birmingham | Alabama | In reclutamento |
| Mohtaseb Cancer Center and Blood Disorders | Bullhead City | Arizona | In reclutamento |
| Gabrail Cancer Center | Canton | Ohio | In reclutamento |
| Cancer & Blood Specialists of Arizona | Casa Grande | Arizona | In reclutamento |
| Carolina Oncology Specialists | Charlotte | North Carolina | In reclutamento |
| Oncology & Hematology Associates of West Broward | Coral Springs | Florida | In reclutamento |
| Baptist Health Corbin | Corbin | Kentucky | In reclutamento |
| Pontchartrain Cancer Center | Covington | Louisiana | In reclutamento |
| Baptist Health Hardin | Elizabethtown | Kentucky | In reclutamento |
| The Melanoma and Skin Cancer Institute | Englewood | Colorado | In reclutamento |
| San Juan Oncology Associates | Farmington | New Mexico | In reclutamento |
| Los Angeles Cancer Network (LACN) | Glendale | California | In reclutamento |
| Southeastern Medical Oncology Center (SMOC) | Goldsboro | North Carolina | In reclutamento |
| The Cancer & Hematology Centers (CHC) | Grand Rapids | Michigan | In reclutamento |
| Onocology Consultants P.A. (Oncology Consultants [OC Houston]) | Houston | Texas | In reclutamento |
| Community Clinical Trials | Kingwood | Texas | In reclutamento |
| Lancaster General Hospital (UPenn) | Lancaster | Pennsylvania | In reclutamento |
| Baptist Health Lexington | Lexington | Kentucky | In reclutamento |
| Cancer Partners of Nebraska | Lincoln | Nebraska | In reclutamento |
| CARTI | Little Rock | Arkansas | In reclutamento |
| Baptist Health Louisville | Louisville | Kentucky | In reclutamento |
| Taylor Cancer Research Center | Maumee | Ohio | In reclutamento |
| Cancer Care Specialists of Illinois (CCSI) | O'Fallon | Illinois | In reclutamento |
| Mid Florida Cancer Centers | Orange City | Florida | In reclutamento |
| Ventura County Hematology Oncology Specialists | Oxnard | California | In reclutamento |
| Oregon Health & Science University (OHSU) | Portland | Oregon | In reclutamento |
| Virginia Cancer Institute | Richmond | Virginia | In reclutamento |
| Mayo Clinic | Rochester | Minnesota | In reclutamento |
| Medical Oncology Associates of San Diego (MOASD) | San Diego | California | In reclutamento |
| Medical Oncology Associates of San Diego | San Diego | California | In reclutamento |
| Guthrie Foundation | Sayre | Pennsylvania | In reclutamento |
| New York Cancer & Blood Specialists | Shirley | New York | In reclutamento |
| Christus Health Highlands | Shreveport | Louisiana | In reclutamento |
| Highlands Oncology Group (HOG) | Springdale | Arkansas | In reclutamento |
| Cox Health | Springfield | Missouri | In reclutamento |
| Comprehensive Hematology Oncology (CHO) | St. Petersburg | Florida | In reclutamento |
| Stockton Hematology Oncology Med Group | Stockton | California | In reclutamento |
| Northwest Medical Specialties (NWMS) | Tacoma | Washington | In reclutamento |
| Christus St. Michael's | Texarkana | Texas | In reclutamento |
| Cotton O'Neil Cancer Center [Stormont Vail] | Topeka | Kansas | In reclutamento |
| Oklahoma Cancer Specialists and Research Institute (OCSRI) | Tulsa | Oklahoma | In reclutamento |
| Carle Health | Urbana | Illinois | In reclutamento |
| Cancer Center of Kansas | Wichita | Kansas | In reclutamento |
| Regional Medical Oncology Center | Wilson | North Carolina | In reclutamento |
| Cancer Care Associates of York (CCAY) | York | Pennsylvania | In reclutamento |
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 24 settembre 2026
Centro aggiunto
45 sites added (47 total)
247